Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer
Sponsor: Tehran University of Medical Sciences
Summary
Uterine cervix cancer can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment which can reduce costs and patient exposure. The aim of our study is to determine the non-inferiority of hypofractionated radiotherapy compared with conventional treatment.
Official title: Comparison of Clinical Response and Toxicity of Hypo-fractionated Chemoradiation With Standard Treatment in Patients With Uterine Cervix Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2021-04-01
Completion Date
2028-03
Last Updated
2021-10-12
Healthy Volunteers
Yes
Conditions
Interventions
Hypofractionated EBRT
EBRT dose of 40Gy in 15 fractions over 3 weeks plus 3 weekly infusions of cisplatin 40mg/m2
Standard EBRT
EBRT dose of 45Gy in 25 fractions over 5 weeks plus 5 weekly infusions of cisplatin 40mg/m2
Locations (1)
Imam Khomeini Hospital Complex
Tehran, Iran